Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Wednesday, July 1
POSTER SESSIONS Track C 33196-33225

33196 Maximizing needle exchange coverage among injection drug users
(IDUs): Do mobile programs attract those at highest risk?
Martin Schechter*; Sue Currie; S.A. Strathdee; M. V O'Shaughnessy;
D.M. Patrick; M.L. Rekart;J. Turvey; M.T Schechver, Canada
33197 Acquisition of sterile needles among injecting drug users admitted
to drug treatment in three U.S. metropolitan areas
Christopher Murrill*; M. Miller; L. Linley; M. Gwinn, USA
33198 Lack of P.W.A. network in Africa
David Kiddie Kasente, Kenya
33199 Residual risk of transfusion-transmitted viral infections (HIV and
other viruses) in France
Josiane Pillonel*; A.M. Couroucd, France
33200 Detection of antibodies to HIV-1 group 0 by eight screening and four
confirmatory assays
Niel Constantine*; R.D. Saville; L. Zekeng; H.A. Anhary; F Ketema; L.
Gurtler, USA
33201 Cost-effectiveness of pooling blood samples for HIV screening
among blood-donors
Alessandro Ghirardini*; Marcello Pagano; R. Bellocco; E. Litvak;
M. Gonzales; X. Xi Tu, Italy
33202 Prevalence of HIV antibodies in replacement blood donors in Delhi
Krishna Ray, India
33203 Peculiarities of AIDS/STDs prevention work by NGO in prison
settings in St. Petersburg Region
Yakov Kucherov, Russia
33204 Ensuring blood safety in Latin American and the Caribbean (LAC):
A cost-effective strategy
Paloma Cuchi*; M. Weissenbacher; G. Schmunis; R. Mazin-Reynoso;
F Zacarias, USA
33205 Blood safety in India through judicial and NGO activism
RR. Gattani*; I.S. Gilada; G. V Bhimani, India
33206 Sero-prevalence of HIV-1 and other blood borne diseases among
blood donors at Queen Elizabeth Hospital, MALAWI
Augustine K. A. Barnaba, Malawi
33207 Sickle cell anaemia and the risk of HIV-infection in Lagos Nigeria
Ibironke Akinsete*; Alani S. Akanmu; R.O. Olatunji; 0.5. Njoku, Nigeria
33208 India marches towards safer blood transfusion!
Jayabaskar Thiyagarajan*; R. Ramanathan Ravinathan;
R. Amudhamozhi Ravinathan; A. Aswathaman Karthikeyan; K. Shibi
Chakravarthi; RT. Thiyagarajan Ravinder; T. Thiyagarajan Mohankumar,
India
33209 Impact of donor selection on HIV-prevalence among blood donors at
the CNTS of Bujumbura in Burundi between 1993 and 1997
Ignancio Nzoyungwanayo*; D. Songore; S. Ciza; B. Ndihokubwmyo;
J. Ntibuhiyim; E. Ndihokubwmyo, Burundi
33210 The effect of HIV educational programmes on blood safety
Dorothy Kyeyune, Uganda
33211 The impact of educational material on the blood donors

knowledge about AIDS
Snezna Levicnik-Stezinar*; C. Gregorc, Slovenia

33212 Community cohorts for HIV-1 vaccine trials in Northern Thailand;
the Thai HIVNET/WRAIR collaboration
Chris Beyrer*; C. Khamboonruang; C. Natpratan; P Cegielski;
P Renzullo; J. McNeil; K.E. Nelson, USA
33213 A recombinant BCG vaccine for HIV-1 protects cynomolgus monkeys
from SHIVMN challenge
Tadashi Nakasone*; K. Someya; Y Ami; K. Shinora; H. Yamamoto;
N. Yoshino; S. Ando; T Asano; L. Yichen; K. Matsuo; H. Yoshikura;
S. Yamazaki; M. Honda, Japan
33214 Feasibility and willingness to participate in HIV Vaccine trials in cohorts
of young men having sex with Men (MSM) and injection drug users (IDUs)
Martin Schechter*; Steffanie Anne Strathdee; M.V. O'Shaughnessy;
J.S.G. Montaner; S.L. Martindale; S.L. Currie; M.T Schechter, Canada
33215 Enabling women to participate in HIV vaccine efficacy trials:
Lessons learned from a U.S. vaccine preparedness study
Pamela Brown-Peterside*; C. Smith; P. Affleck; P Doherty-lddings;
R. Borden; C. Clark; C. Harrison, USA
33216 AVEG 031:Phase I evaluation of a gag-pol facilitated DNA vaccine for
HIV-1 prevention
Paul Goepfert*; Mark Mulligan; L. Corey; B. Graham; T Evans;
K. Weinhold; D. Stablein; R. Ginsberg, USA
33217 Feasibility of clinical trials with candidate HIV/AIDS vaccines in Brazil
Dirceu B. Greco*; J.R. Carvalheiro; F Sutmoller; E.A. Castilho; P Chequer,
Brazil
33218 Determination of prevalent HIV-1 subtypes in South Africa and the
construction of a gp120 DNA vaccine
Joanne van Harmelen*; H. Bredell; L. Morris; E. van der Ryst; S. Lyons;
D. York; C Williamson, South Africa
33219 Recruitment of volunteers into a randomized, placebo controlled
phase I HIV-1 vaccine trial in Uganda
Anthony Kebba*; C. Othiendo; K. George; D. Hom; P. Mugyenyi;
R. Mugerwa;J. Ellner, Uganda
33220 Clinical response to HIV Thai E/MF59 vaccine administer of alone or
combined with SF2 gp 120 antigen in healthy volunteers
Punnee Pitisuttithum*; C. Khamboonruang; P Suntharasamai; 5.
Thongsawat;S.Migasena; Y Yutabutr; B. Phonrat, Thailand
33221 CTL and Neutralizing (Nt) Antibody (Ab) responses with a
Combination HIV-1 vaccine regimen
Lawrence Corey*; K. Weinhold; D. Montefiori; D. Stablein, USA
33222 Future Planning for HIV Vaccine Evaluation of Thai AIDS
Vaccine Evaluation Group (TAVEG) in Thailand
Prasert Thongcharden;S. Migasena; C. Khamboonruang;
S. Nitayaphan; A. Brown; C Wasi, Thailand
33223 AIDSVAX B/B and AIDSVAX B/E. Likely to protect. But how well
and for how long must await results of planned efficacy trials
Donald Francis*; RW. Berman; S. Migasena; D. Kitayaporn; T. Gregory, USA
33224 Selection of an appropriate adjuvantfor vaccination with HIV-1 derived
Multi-Epitope Polypeptides (MEPs)
Antonieta M. Herrera*; D.V Vazquez; D.Q. Quintana; L.N. Navea;
L.L. Lobaina; A.N. Napoles; C.D. Duarte, Cuba

33225 Feasibility and results of a HIV-incidence cohort of homo/bisexual
men in Belo Horizonte, Brazil - 3 year report of the project Horizonte
Marilia Greco*; E. Oliveira; R.C. Domingues; J.C. Andrade; C.M. Antunes,
Brazil

154

12th World AIDS Conference Geneva